IDbyDNA’s Explify® platform will be used to analyze pathogens and immune reaction in cerebrospinal fluid of pediatric patients.
IDbyDNA will license the Explify® platform for Fleury’s utilization in high quality clinical NGS-based metagenomic testing. Fleury labs provide healthcare analysis services across South America, with over 9,100 employees and 2,100 physicians.
In the winter 2018 issue of their Magnify Magazine, our partner ARUP Laboratories discusses how they leveraged the Explify Platform to develop their Explify Respiratory test. Read more to learn how metagenomic testing is shifting the paradigm in the approach infectious disease diagnosis.
IDbyDNA and Locus Biosciences are partnering to develop companion precision diagnostics for patients with drug-resistant Pseudomonas aeruginosa infections who will benefit from Locus’ precision antimicrobials.
PM360’s annual guide was established to provide a comprehensive overview of the latest advancements within healthcare and life sciences and offers brief profiles of each compelling innovation selected.
Metagenomics test identified pathogens missed by conventional lab tests in 44 percent of immunocompromised children treated for respiratory infection.
First test for pneumonia caused by previously undetected pathogen will be available through ARUP’s established national clinical network.
Using the metagenomics analysis tool Taxonomer, researchers have been able to quickly tease out what pathogens are present in clinical and other samples.
More effective pathogen identification will improve our understanding of pneumonia and guide treatment and site of care decisions.
IDbyDNA makes the “Top 20 Disruptive Projects in Drug Development Data Analytics” as it brings Precision Medicine to Infectious Disease.
In contrast to most of our current tests, you can use a metagenomic approach to find any and all potential pathogens in a patient sample without having to know what you’re looking for,” says Robert Schlaberg.
IDbyDNA, a precision medicine company focused on metagenomic approaches for infectious disease identification, today announced publication results in the New England Journal of Medicine that its metagenomics tool, Taxonomer, was used in the identification of Zika virus genomic sequence in the first Zika virus-related death in the continental U.S.
IDbyDNA announced today that it has closed $9 million in Series A financing. ARTIS Ventures led the round, with additional investments from ARUP Laboratories and other private investors.
To determine the cause of certain diseases, scientists break open cells, extract the DNA and RNA and sequence them, a technique used for genome sequencing, now used in diagnostic labs.
Pathogens like bacteria, fungi, viruses and parasites can give us illnesses ranging from a nagging cold to a life-threatening Staph infection. With its speed, accuracy, and user-friendliness, Taxonomer is pushing patient care, diagnostics, and basic science to new heights.
Rapid identification of pathogens is vital for the accurate diagnosis and treatment of infectious diseases. A new bioinformatics tool that analyses and visualizes metagenomics data promises to speed up this process to a matter of minutes.
Scientists from the University of Utah, ARUP Laboratories, and bioinformatics startup IDbyDNA have developed Taxonomer, a metagenomics analysis platform for universal pathogen detection and host-response profiling.
In a paper published today in Genome Biology, IDbyDNA and collaborators demonstrated the ability of Taxonomer to analyze the sequences of all nucleic acids in a clinical specimen (DNA and RNA) and to detect pathogens, as well as profile the patient’s gene expression, in a matter of minutes.